FOLH1 and prostate cancer: In this study, we combined the PSMA ligand-mediated delivery of ASOs with N-alkanesulfonyl phosphoramidate groups, mesyl and busyl (Figure 1A) to achieve efficient knockdown of Malat1 lncRNA in prostate cancer cells in vitro.